Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Clinical trial NCT02704858 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02704858
- Sponsor
- Neonc Technologies, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-08-01
- Primary completion
- 2026-07-30
- Enrollment
- 49
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.